Integra LifeSciences Holdings has signed an agreement with medical device firm Tornier to acquire the US rights of its Salto Talaris and Salto XT ankle replacement products and Futura silastic toe replacement products.

Terms of the deal have not been disclosed.

The deal will also provide an option to Integra to acquire the rights of the Salto Talaris, Salto XT, Salto Mobile and Futura silastic toe replacement products outside the US, in the future.

Integra’s orthopedics and tissue technologies business president Mark Augusti said: "This acquisition broadens our extremity product portfolio by adding commercially available products."

Tornier president and CEO David Mowry said: "We are pleased with reaching this point in the divestiture process as well as with the quality of the buyer for these assets and to have completed this important step toward our pending merger with Wright."

The deal is subject to approval by the US Federal Trade Commission (FTC) and the closure of the pending merger of Tornier and Wright Medical Group, which is expected to complete in the third quarter of this year.

Integra provides solutions, including regenerative technologies, specialty surgical solutions, orthopedics and tissue technologies.